<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fosfomycin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fosfomycin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fosfomycin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11947" href="/d/html/11947.html" rel="external">see "Fosfomycin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="126342" href="/d/html/126342.html" rel="external">see "Fosfomycin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F174319"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Monurol [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866984"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ivozfo;</li>
<li>JAMP-Fosfomycin;</li>
<li>Monurol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F174353"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F174323"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection: IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="14986f4d-5f9f-4991-8dc0-20fbc22a09d1">Bone and joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone and joint infection:</b>
<b>IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e295a26-b8e0-4163-a420-69cc1b956ecb">Endocarditis, infective</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, infective:</b>
<b>IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b>
<b>IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b>
<b>IV</b> [Canadian product]: 16 to 24 g/day in 3 to 4 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated:</b>
<b>IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="73dd0fd0-3797-4a51-80c7-c226a305d786">Prostatitis, chronic bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostatitis, chronic bacterial (alternative agent) (off-label use): Note: </b>Reserve for use when other options are not appropriate because of resistance or intolerance. The optimal dose has not been established; the following are some suggested dosing regimens:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 3 g every 2 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26666924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26666924'])">Ref</a></span>) <b>or</b> 3 g once daily for 1 week followed by 3 g once every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30796442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30796442'])">Ref</a></span>). Duration is ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30796442','lexi-content-ref-26666924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30796442','lexi-content-ref-26666924'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8393ad2f-5f04-4843-b3ac-9564d4127696">Skin and soft tissue infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, complicated:</b>
<b>IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>). Reserve high-dose regimens (&gt;16 g/day) for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic bacteriuria (≥10<sup>5</sup> CFU per mL) in pregnancy</i>: <b>Oral:</b> 3 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19768649','lexi-content-ref-Gupta.4','lexi-content-ref-Nicolle.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19768649','lexi-content-ref-Gupta.4','lexi-content-ref-Nicolle.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection), treatment:</i>
<b>Oral:</b> 3 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.2','lexi-content-ref-Gupta.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.2','lexi-content-ref-Gupta.1','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Multidose regimens (eg, 3 g once every 2 to 3 days for 3 doses) have been described, particularly for multidrug-resistant UTIs; however, it is unknown whether these have greater efficacy than single-dose therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307867','lexi-content-ref-27788499','lexi-content-ref-28295441','lexi-content-ref-22926565','lexi-content-ref-24309172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307867','lexi-content-ref-27788499','lexi-content-ref-28295441','lexi-content-ref-22926565','lexi-content-ref-24309172'])">Ref</a></span>). Fosfomycin may be less effective than other first-line agents, although data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29710295','lexi-content-ref-21292654','lexi-content-ref-9255237','lexi-content-ref-10890258','lexi-content-ref-8298585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29710295','lexi-content-ref-21292654','lexi-content-ref-9255237','lexi-content-ref-10890258','lexi-content-ref-8298585'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, prophylaxis for recurrent infection (alternative agent)</i>: <b>Note:</b> May be considered in nonpregnant women with bothersome, frequently recurrent cystitis despite nonantimicrobial preventive measures. The optimal duration has not been established; duration ranges from 3 to 12 months, with periodic reassessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-Gupta.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-Gupta.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous prophylaxis: Oral: 3 g once every 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-24554302','lexi-content-ref-16080282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-24554302','lexi-content-ref-16080282'])">Ref</a></span>). <b>Note:</b> Some experts use a shorter dosing interval (eg, every 3 to 4 days), but there is no clinical evidence that this is more effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis):</i>
<b>Note:</b> Some experts reserve use for multidrug-resistant infections when other options are not appropriate because of resistance or intolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27956267','lexi-content-ref-26923259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27956267','lexi-content-ref-26923259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b> [Canadian product]: 12 to 24 g/day in 2 to 3 divided doses (maximum: 8 g/<b>dose</b>) (manufacturer's labeling). Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991676"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). However, elimination is significantly prolonged in patients with CrCl &lt;50 mL/minute; monitor closely for adverse effects and tolerability, particularly with prolonged therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV [Canadian product]:</b>
<b>
<sup></sup>Note: </b>Dose recommendations are based on expert opinion derived from pharmacokinetic modeling and limited clinical data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30861061','lexi-content-ref-32961833','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30861061','lexi-content-ref-32961833','lexi-content-ref-Manu.1'])">Ref</a></span>); safety and efficacy of dose adjustments have not been fully evaluated in clinical trials.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Fosfomycin Dose Adjustments for Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">% of indication-specific recommended daily dose to be administered</p></th>
<th align="center">
<p style="text-indent:0em;">Frequency</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Estimated using the Cockcroft-Gault formula (manufacturer’s labeling).</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>The initial (loading) dose should be increased to twice the maintenance dose; not to exceed 8 g (manufacturer’s labeling). For example, if the maintenance dose is 4 g then the loading dose should be 8 g.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Reserve dose regimens in the higher part of the range for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin (ie, where higher dosages [&gt;16 g/day] would be considered in patients with normal kidney function) (expert opinion).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">40 to 130 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">100%</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 4 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;40 mL/minute<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">~75% (range: 70% to 80%<sup>c</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 to &lt;30 mL/minute<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">~60% (range: 50% to 70%<sup>c</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;20 mL/minute<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">~40% (range: 30% to 50%<sup>c</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 divided doses</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;10 mL/minute<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">~20% (range: 20% to 30%<sup>c</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 divided doses</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer maximum indication-specific doses (usually 24 g/day in 3 to 4 divided doses except for urinary tract infections) (expert opinion derived from limited clinical data) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880170','lexi-content-ref-26239990']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880170','lexi-content-ref-26239990'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (extensively removed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3383462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3383462'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary. However, elimination is significantly prolonged in patients on dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3383462','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3383462','lexi-content-ref-Manu.1'])">Ref</a></span>); monitor closely for adverse effects and tolerability, particularly with prolonged therapy. When scheduled dose falls on a dialysis day, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 2 to 4 g, then 2 to 4 g three times weekly post hemodialysis (expert opinion derived from (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3383462','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3383462','lexi-content-ref-Manu.1'])">Ref</a></span>)). Reserve higher-dose regimens for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin (ie, where higher dosages [&gt;16 g/day] would be considered in patients with normal kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary. However, elimination is significantly prolonged in patients on dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3383462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3383462'])">Ref</a></span>); monitor closely for toxicity and tolerability, particularly with prolonged therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 to 4 g every 48 hours (expert opinion derived from (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3383462','lexi-content-ref-22564843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3383462','lexi-content-ref-22564843'])">Ref</a></span>)). Reserve higher-dose regimens for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin (ie, where higher dosages [&gt;16 g/day] would be considered in patients with normal kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important. <b>Note:</b> Very little clinical data.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 6 to 8 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16782745','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16782745','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Reserve higher-dose regimens for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin (ie, where higher dosages [&gt;16 g/day] would be considered in patients with normal kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4 to 6 g once daily followed by a 4 to 6 g supplemental dose after each PIRRT session (expert opinion derived from limited clinical data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27272722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27272722'])">Ref</a></span>)). Reserve higher-dose regimens for severe infections known or suspected to be caused by organisms with decreased susceptibility to fosfomycin (ie, where higher dosages [&gt;16 g/day] would be considered in patients with normal kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988989"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV [Canadian product]: No dosage adjustment necessary.</p></div>
<div class="block doo drugH1Div" id="F57457733"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">IV [Canadian product]: BMI &gt;38 kg/m<sup>2</sup>: 16 to 24 g/day may be needed depending on site and severity of infection.</p></div>
<div class="block doe drugH1Div" id="F174324"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53894203"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="126342" href="/d/html/126342.html" rel="external">see "Fosfomycin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Fosfomycin tromethamine (Monurol):</b></i></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aef3665-b206-47be-ac86-180f5fa7d6b5">Urinary tract infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, uncomplicated: </b>Limited data available: <b>Note:</b> Oral formulation should not be used for pyelonephritis or perinephric abscess.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years: Oral: 2,000 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31131593','lexi-content-ref-3652281','lexi-content-ref-2085989','lexi-content-ref-3552696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31131593','lexi-content-ref-3652281','lexi-content-ref-2085989','lexi-content-ref-3552696'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 3,000 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31131593','lexi-content-ref-10890258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31131593','lexi-content-ref-10890258'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Fosfomycin sodium (Ivozfo [Canadian product]):</b></i>
<b>Note:</b> High-dose regimens (&gt;300 mg/kg/day for ≤40 kg and &gt;16 <b>g</b>/day for &gt;40 kg) may be considered for severe infections known or suspected to be caused by organisms with moderate susceptibility. Data is limited for doses &gt;16 <b>g</b>/day, monitor closely.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;10 kg: 200 to 300 mg/kg/<b>day</b> in 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 40 kg: 200 to 400 mg/kg/<b>day</b> in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: 16 to 24 <b>g/day</b> in 3 to 4 divided doses; maximum dose: 8 <b>g</b>/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;10 kg: 200 to 300 mg/kg/<b>day</b> in 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 40 kg: 200 to 400 mg/kg/<b>day</b> in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: 12 to 24 <b>g/day</b> in 2 to 3 divided doses; maximum dose: 8 <b>g</b>/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e222b4ae-d4fc-4c2a-9a63-872bcae28c47">Respiratory tract infection, nosocomial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory tract infection (lower), nosocomial:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;10 kg: 200 to 300 mg/kg/<b>day</b> in 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 40 kg: 200 to 400 mg/kg/<b>day</b> in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: 12 to 24 <b>g/day</b> in 2 to 3 divided doses; maximum dose: 8 <b>g</b>/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;10 kg: 200 to 300 mg/kg/<b>day</b> in 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 40 kg: 200 to 400 mg/kg/<b>day</b> in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;40 kg: 12 to 16 <b>g/day</b> in 2 to 3 divided doses; maximum dose: 8 <b>g</b>/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53894284"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Fosfomycin tromethamine (Monurol): There are no dosage adjustments provided in the manufacturer's labeling; however, in adults with renal impairment (CrCl 7 to 54 mL/minute) the amount of fosfomycin recovered in the urine was lower, suggesting decreased renal excretion.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Fosfomycin sodium (Ivozfo [Canadian product]):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: There are no pediatric-specific recommendations; based on experience in adult patients, dosage adjustment suggested.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;80 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;40 to 80 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; use with caution at recommended doses (especially the higher end of the recommended range).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 mL/minute: Administer 70% of the recommended daily dose (based on indication) in 2 to 3 divided doses; first dose (loading dose) should be doubled but should not exceed 8 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 mL/minute: Administer 60% of the recommended daily dose (based on indication) in 2 to 3 divided doses; first dose (loading dose) should be doubled but should not exceed 8 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 mL/minute: Administer 40% of the usual recommended daily dose (based on indication) in 2 to 3 divided doses; first dose (loading dose) should be doubled but should not exceed 8 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 mL/minute: Administer 20% of the usual recommended daily dose (based on indication) in 1 to 2 divided doses; first dose (loading dose) should be doubled but should not exceed 8 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent: Patients undergoing hemodialysis every 48 hours should receive fosfomycin 2 <b>g</b> at the end of dialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">CVVH (post dilution): No dosage adjustment necessary in patients undergoing <b>postdilution</b> CVVH; there are no dosage adjustments provided in the manufacturer's labeling (has not been studied) for patients undergoing <b>predilution</b> CVVH.</p></div>
<div class="block dohp drugH1Div" id="F53894292"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Fosfomycin tromethamine (Monurol): There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Fosfomycin sodium (Ivozfo [Canadian product]): Infants, Children, and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F58646138"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection has occurred with oral fosfomycin, including <b>
<i>Clostridioides difficile</i></b>
<b>-associated diarrhea </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26921414','lexi-content-ref-29891606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26921414','lexi-content-ref-29891606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; related to cumulative antibiotic exposure. Fosfomycin may cause disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as <i>C. difficile</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-21653301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-21653301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>). <i>C. difficile</i> has been reported within 30 days of fosfomycin therapy, including up to 14 days after the last dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26921414','lexi-content-ref-29891606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26921414','lexi-content-ref-29891606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Antiulcer medications (eg, proton pump inhibitors, H<sub>2</sub> blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2023','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Electrolyte disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">IV fosfomycin [Canadian product] is associated with electrolyte abnormalities, including hypernatremia, hypokalemia, hypomagnesemia, and hypophosphatemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27956267','lexi-content-ref-29660401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27956267','lexi-content-ref-29660401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hypernatremia and hypokalemia are the most common electrolyte disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27956267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27956267'])">Ref</a></span>). Electrolyte abnormalities are typically mild; however, reports of severe hypernatremia have occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27956267','lexi-content-ref-35422698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27956267','lexi-content-ref-35422698'])">Ref</a></span>). Electrolyte supplementation may be required in ~10% to 20% of patients receiving IV fosfomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29660401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29660401'])">Ref</a></span>). Several cases of hypernatremia have been associated with the incorrect reconstitution of the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35422698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35422698'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; each gram of IV fosfomycin contains ~0.32 g of sodium, creating a fluid and sodium imbalance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35422698','lexi-content-ref-28901793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35422698','lexi-content-ref-28901793'])">Ref</a></span>). Fosfomycin may also increase the urinary excretion of potassium in the distal part of the renal tubules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28901793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28901793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; electrolyte abnormalities often occur while receiving active therapy and hypokalemia has been reported within 4 days of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21074377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21074377'])">Ref</a></span>); however, the duration of therapy may impact the risk.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fosfomycin is associated with <b>abdominal pain</b>, <b>dyspepsia</b>, <b>nausea</b>, and non-<i>Clostridioides difficile</i>
<b>diarrhea</b>. GI disturbances have been reported for both oral and IV [Canadian product] formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27956267','lexi-content-ref-29660401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27956267','lexi-content-ref-29660401'])">Ref</a></span>). GI symptoms associated with oral fosfomycin are typically mild, self-limiting (within 1 to 2 days), and do not usually require discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21945848','lexi-content-ref-9098664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21945848','lexi-content-ref-9098664'])">Ref</a></span>). Diarrhea is the most common GI adverse reaction with oral fosfomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29891606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29891606'])">Ref</a></span>). Compared with ciprofloxacin for the treatment of urinary tract infections, daily oral fosfomycin caused more GI adverse reactions; however, there was not a greater rate of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34791074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34791074'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; within approximately the first week after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34791074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34791074'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (immediate and delayed) have been reported and range from <b>skin rash </b>to rare cases of <b>anaphylaxis</b> and <b>anaphylactic shock</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36521785','lexi-content-ref-21354031','lexi-content-ref-26437630','lexi-content-ref-9788697','lexi-content-ref-20800792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36521785','lexi-content-ref-21354031','lexi-content-ref-26437630','lexi-content-ref-9788697','lexi-content-ref-20800792'])">Ref</a></span>). Delayed hypersensitivity reactions, including severe cutaneous adverse reactions (SCARs) (<b>drug reaction with eosinophilia and systemic symptoms</b> [DRESS], <b>Stevens-Johnson syndrome</b> [SJS], <b>toxic epidermal necrolysis</b> [TEN], and <b>acute generalized exanthematous pustulosis</b> [AGEP]), have been reported but may not have been the only implicated drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26437630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26437630'])">Ref</a></span>). Acute localized exanthematous pustulosis (ALEP) has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37250012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37250012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) can be non–IgE-mediated or IgE-mediated. Delayed hypersensitivity reactions, including rash and SCARs, are commonly T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration, but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Nonspecific rash: Intermediate; generally occur 7 to 10 days after initiation. Other reactions (including SCARs): Varied; typically occur a few days up to 2 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F174290"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with the oral formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), diarrhea (9% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, dyspepsia (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Dyspepsia table link" class="lexi-table-link" data-table-id="lexi-content-dyspepsia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspepsia')">table 2</a>)</span><span class="table-link" style="display:none;">Dyspepsia</span>, nausea (4% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 3</a>)</span><span class="table-link" style="display:none;">Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Fosfomycin: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fosfomycin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nitrofurantoin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Trimethoprim/Sulfamethoxazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ciprofloxacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fosfomycin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nitrofurantoin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trimethoprim/Sulfamethoxazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ciprofloxacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reported regardless of drug relationship</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">374</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">428</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reported as drug-related</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspepsia" frame="border" id="lexi-content-dyspepsia" rules="all">
<caption style="text-align:center;">
<b>Fosfomycin: Adverse Reaction: Dyspepsia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fosfomycin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nitrofurantoin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Trimethoprim/Sulfamethoxazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ciprofloxacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fosfomycin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nitrofurantoin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trimethoprim/Sulfamethoxazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ciprofloxacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reported regardless of drug relationship</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">374</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">428</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reported as drug-related</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Fosfomycin: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fosfomycin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nitrofurantoin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Trimethoprim/Sulfamethoxazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ciprofloxacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fosfomycin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nitrofurantoin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trimethoprim/Sulfamethoxazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ciprofloxacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reported regardless of drug relationship</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">374</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">428</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reported as drug-related</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (3%), vaginitis (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (1% to 2%), dizziness (1% to 2%), headache (4% to 10%), pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (3%), rhinitis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abnormal stools, anorexia, constipation, flatulence, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, insomnia, migraine, nervousness, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Iarikov 2015), Stevens-Johnson syndrome (Iarikov 2015), toxic epidermal necrolysis (Iarikov 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea (Wenzler 2018), toxic megacolon</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Iarikov 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Iarikov 2015), anaphylaxis (Iarikov 2015), angioedema (Iarikov 2015), drug reaction with eosinophilia and systemic symptoms (Iarikov 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of asthma</p></div>
<div class="block coi drugH1Div" id="F5996052"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to fosfomycin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F5996053"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: IV [Canadian product]: Agranulocytosis and neutropenia have been reported with use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Hepatic injury, including steatosis and hepatitis, has been reported; usually reversible upon discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte disturbances: Electrolyte disturbances may occur. Use with caution in patients with cardiac insufficiency, hypertension, hyperaldosteronism, hypernatremia, hypoalbuminemia, nephrotic syndrome, pulmonary edema, or hepatic cirrhosis. Hypokalemia may cause cardiac arrhythmia, edema, hyporeflexia, muscle twitching, tiredness, and weakness.</p></div>
<div class="block foc drugH1Div" id="F174298"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Monurol: 3 g (1 ea [DSC]) [orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F174284"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F4370642"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Fosfomycin Tromethamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 g (per each): $72.00 - $100.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866985"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Monurol: 3 g (3 g) [contains saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3 g (3 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ivozfo: 4 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F174301"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Always mix with 3 to 4 oz (90 to 120 mL) cool water before ingesting; do not administer in its dry form or mix with hot water. May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV</b> [Canadian product]: Infuse 2 g dose over ≥15 minutes; 4 g dose over ≥30 minutes; and 8 g dose over ≥60 minutes. Consider extended infusion time (≤4 hours for the 4 or 8 g dose) or reduction in individual dose with more frequent administration in patients at high risk for hypokalemia.</p></div>
<div class="block admp drugH1Div" id="F53894296"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Oral packet: Do not administer in its dry form; must be mixed with water prior to administration. May be administered without regard to meals. Pour contents of 3 g packet into 3 to 4 oz (90 to 120 mL) of water (not hot) and stir to dissolve; the resultant concentration is 25 to 33.3 mg/mL. Measure appropriate volume for desired dose and take immediately. Discard any remaining solution.</p>
<p style="text-indent:-2em;margin-left:2em;">IV [Canadian product]: Infuse 2 g dose over ≥15 minutes, 4 g dose over ≥30 minutes, or 8 g dose over ≥60 minutes. Consider extended infusion time (up to 4 hours for the 4 g or 8 g dose) in patients at high risk for hypokalemia.</p></div>
<div class="block use drugH1Div" id="F174299"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral packet:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cystitis, acute uncomplicated:</b> Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of <i>Escherichia coli</i> and <i>Enterococcus faecalis</i>.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin, other therapeutic agents should be selected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV [Canadian product]: Note:</b> Reserve for use when it is considered inappropriate to use commonly recommended antibacterial agents, or when these alternative antibacterial agents have failed to demonstrate efficacy. Fosfomycin should usually be used as part of a combination antibacterial regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bloodstream infection:</b> Treatment of bloodstream infection associated with bacterial meningitis; bone and joint infections; complicated intra-abdominal infections; complicated skin and soft tissue infections; complicated urinary tract infections; hospital-acquired pneumonia, including ventilator-associated pneumonia; or infective endocarditis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bone and joint infection:</b> Treatment of bone and joint infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endocarditis:</b> Treatment of infective endocarditis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intra-abdominal infection:</b> Treatment of complicated intra-abdominal infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Meningitis, bacterial: </b>Treatment of bacterial meningitis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pneumonia, hospital-acquired or ventilator-associated: </b>Treatment of hospital-acquired, including ventilator-associated, pneumonia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Skin and soft tissue infection:</b> Treatment of complicated skin and soft tissue infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Urinary tract infection: </b>Treatment of complicated urinary tract infection.</p></div>
<div class="block off-label drugH1Div" id="F25725556"><span class="drugH1">Use: Off-Label: Adult</span><p>Prostatitis, chronic bacterial</p></div>
<div class="block mst drugH1Div" id="F174359"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Monurol may be confused with Monopril</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299365"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F174292"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): May decrease the serum concentration of Fosfomycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F5996050"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fosfomycin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following use of fosfomycin during pregnancy are available (Benevent 2023; Konwar 2022; Mannucci 2019; Philipps 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Fosfomycin is approved for the treatment of urinary tract infections. Untreated asymptomatic bacteriuria may increase the risk of adverse pregnancy outcomes, including the risk of pyelonephritis, preterm labor, and delivery of low-birth-weight infants; treatment with an appropriate antibiotic is recommended (Nicolle [IDSA 2019]). Single dose fosfomycin is effective for the treatment of asymptomatic bacteriuria in pregnant patients (Nicolle [IDSA 2019]; Schulz 2022; Wang 2020). Additional studies are needed to evaluate the effect on outcomes, such as reducing the risk of preterm labor or preventing pyelonephritis (Nicolle [IDSA 2019]). Avoid use in patients at risk for preterm birth when treatment with prolonged antibiotic therapy may be indicated (Betschart 2020).</p></div>
<div class="block brc drugH1Div" id="F7277079"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Fosfomycin is present in breast milk (Kirby 1977).</p>
<p style="text-indent:-2em;margin-left:2em;">Following injection of fosfomycin 1 to 2 grams to 2 women, breast milk concentrations were 3.6 mcg/mL (postpartum age and time of breast milk sampling not provided) (Kirby 1977).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F53498069"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F174296"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">IV [Canadian product]: Electrolytes (sodium, potassium, and phosphate) and fluid balance regularly, in particular for patients receiving digoxin or when using the high-dose regimen (&gt;16 g/day in adults and pediatric patients weighing &gt;40 kg; &gt;300 mg/kg/day in pediatric patients ≤40 kg); leukocyte count; renal function; sodium overload in patients with hepatic cirrhosis.</p></div>
<div class="block pha drugH1Div" id="F174287"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a phosphonic acid derivative, fosfomycin inhibits bacterial wall synthesis (bactericidal) by inactivating the enzyme, pyruvyl transferase, which is critical in the synthesis of cell walls by bacteria.</p></div>
<div class="block phk drugH1Div" id="F174303"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapidly absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: V<sub>d</sub>: 90 to 180 L.</p>
<p style="text-indent:-2em;margin-left:4em;">IV [Canadian product]: 0.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: None.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Fasting: 37%; With food: 30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 3 to 8 hours; CrCl &lt;54 mL/minute: 50 hours; Hemodialysis patients: 40 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV [Canadian product]: ~2 hours; Elderly and/or critically ill patients: 3.6 to 3.8 hours; CVVHF: 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 2 hours; Within 4 hours with high-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Urine (38% as unchanged drug); feces (18% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">IV [Canadian product]: Urine (80% to 90% as unchanged drug); feces (&lt;1% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51192665"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Oral: Urinary excretion decreases to 11% in patients with CrCl 7 to 54 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F174308"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fosfomicina Luar | Veramina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt | Fosfomycin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Fosfomax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fosfocin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Monuril</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Monuril</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Monuril</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fosfomycin dinatrium | Fosfomycin dinitri | Fu mei xin | Li ke te | Monurol | Xin ya mai lin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fomaxin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fosfomycin eberth | Infectofos</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fosfocil | Fosfomicina sintesis | Fosmicin | Luxol | Uroprin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fosfocina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fosfocina</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fosfocina</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fosfomycin Infectopharm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt | Fosfocina | Fosfocine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alexi | Fomicyt</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Focyn | Fosfomycin | Fosmicin | Fosmidex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bdfosfo | Crifos | Fonyl | Fosfocide | Fosfofic | Fosfojoy | Fosfotas | Fosjet | Icufos | Lupifos | Samfos</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fosfocin | Infectofos</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bluebacirin | Eukocin | Forocyle s | Foskoricin | Fosmicin | Frazemicin | Harosmin | Hoskarize | Hoskarize s | Isoramycin | Perexine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fonfocin | Fonofos | Fosfocin | Fosfomycin | Frazemicin | Jw fosfomycin sodium</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Alexi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Infectofos</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fosfocina</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fosfocil | Fosfomicina Antibioticos | Fosune</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fosfomycin Infectopharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fosmicin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fosfobiotic | Fosfocil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Focin | Fosfomycin | Fosforin | Fosomin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt | Infectofos</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fosfomycin tromethamine</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fosfolag</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fosfomycin | Fosmicin | Urobactocin | Urofosfabol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fosfocin | Fosfomycin Infectopharm</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fosfocina intravenosa | Infectofos</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fosfomin | Fosmicin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fomicyt | Fosfocine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fosit</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fofocin | Fosfocina | Fosfomycin | Fosmicin s | Kinfomycin | Ufo</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fosmicin | Phosphoral</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fosfocina | Fosfomicina</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15266443">
<a name="15266443"></a>Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. <i>Cochrane Database Syst Rev</i>. 2004;(3):CD001209. doi:10.1002/14651858.CD001209.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/15266443/pubmed" id="15266443" target="_blank">15266443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37250012">
<a name="37250012"></a>Alfuraih I, Shadid A, Alekrish K, Aleissa M. Acute localized exanthematous pustulosis induced by fosfomycin. <i>JAAD Case Rep</i>. 2023;36:48-50. doi:10.1016/j.jdcr.2023.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/37250012/pubmed" id="37250012" target="_blank">37250012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31042112">
<a name="31042112"></a>Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract Infections in women: AUA/CUA/SUFU guideline. <i>J Urol</i>. 2019;202(2):282-289. doi:10.1097/JU.0000000000000296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/31042112/pubmed" id="31042112" target="_blank">31042112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31307867">
<a name="31307867"></a>Babiker A, Clarke L, Doi Y, Shields RK. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: a real-world perspective and review of the literature [published online June 24, 2019]. <i>Diagn Microbiol Infect Dis</i>. doi:10.1016/j.diagmicrobio.2019.06.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/31307867/pubmed" id="31307867" target="_blank">31307867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31131593">
<a name="31131593"></a>Baquero-Artigao F, Del Rosal Rabes T. Fosfomycin in the pediatric setting: Evidence and potential indications. <i>Rev Esp Quimioter</i>. 2019;32(suppl 1):S55-S61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/31131593/pubmed" id="31131593" target="_blank">31131593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35689790">
<a name="35689790"></a>Benevent J, Araujo M, Beau AB, et al. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database. <i>Infection</i>. 2023;51(1):137-146. doi:10.1007/s15010-022-01861-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/35689790/pubmed" id="35689790" target="_blank">35689790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32365216">
<a name="32365216"></a>Betschart C, Albrich WC, Brandner S, et al. Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy.<i> Swiss Med Wkly.</i> 2020;150:w20236. doi:10.4414/smw.2020.20236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/32365216/pubmed" id="32365216" target="_blank">32365216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36521785">
<a name="36521785"></a>Beyens M, Pint D, Toscano A, Ebo D, Sabato V. A confirmed fosfomycin-induced mast cell activation with anaphylaxis. <i>Ann Allergy Asthma Immunol</i>. 2023;130(3):367-368. doi:10.1016/j.anai.2022.12.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/36521785/pubmed" id="36521785" target="_blank">36521785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3383462">
<a name="3383462"></a>Bouchet JL, Albin H, Quentin C, et al. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. <i>Clin Nephrol</i>. 1988;29(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/3383462/pubmed" id="3383462" target="_blank">3383462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4006330">
<a name="4006330"></a>Bouchet JL, Quentin C, Albin H, Vinçon G, Guillon J, Martin-Dupont P. Pharmacokinetics of fosfomycin in hemodialyzed patients. <i>Clin Nephrol</i>. 1985;23(5):218-221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/4006330/pubmed" id="4006330" target="_blank">4006330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3652281">
<a name="3652281"></a>Careddu P, Borzani M, Scotti L, Varotto F, Garlaschi L, Fontana P. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid. <i>Chemioterapia</i>. 1987;6(4):290-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/3652281/pubmed" id="3652281" target="_blank">3652281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2023">
<a name="CDC.2023"></a>Centers for Disease Control and Prevention (CDC). <i>C. diff </i>(<i>Clostridioides difficile</i>). Last reviewed October 25, 2022. Accessed September 15, 2023. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24554302">
<a name="24554302"></a>Costantini E, Zucchi A, Salvini E, et al. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial.<i> Int Urogynecol J</i>. 2014;25(9):1173-1178. doi:10.1007/s00192-013-2318-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/24554302/pubmed" id="24554302" target="_blank">24554302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19768649">
<a name="19768649"></a>Estebanez A, Pascual R, Gil V, Ortiz F, Santibáñez M, Pérez Barba C. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. <i>Eur J Clin Microbiol Infect Dis</i>. 2009;28(12):1457-1464. doi:10.1007/s10096-009-0805-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/19768649/pubmed" id="19768649" target="_blank">19768649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team:Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc,FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21074377">
<a name="21074377"></a>Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. <i>Int J Antimicrob Agents</i>. 2011;37(1):82-83. doi:10.1016/j.ijantimicag.2010.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/21074377/pubmed" id="21074377" target="_blank">21074377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9255237">
<a name="9255237"></a>Fosfomycin for urinary tract infections. <i>Med Lett Drugs Ther</i>. 1997;39(1005):66-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/9255237/pubmed" id="9255237" target="_blank">9255237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21354031">
<a name="21354031"></a>Gamboa PM, Antepara I, Jauregui I, Urrutia I, Sanz ML. Two patients with anaphylactic shock due to fosfomycin. <i>Ann Allergy Asthma Immunol</i>. 2011;106(3):260-261. doi:10.1016/j.anai.2010.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/21354031/pubmed" id="21354031" target="_blank">21354031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782745">
<a name="16782745"></a>Gattringer R, Meyer B, Heinz G, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. <i>J Antimicrob Chemother</i>. 2006;58(2):367-371. doi:10.1093/jac/dkl251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/16782745/pubmed" id="16782745" target="_blank">16782745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27788499">
<a name="27788499"></a>Giancola SE, Mahoney MV, Hogan MD, Raux BR, McCoy C, Hirsch EB. Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient characteristics and outcomes. <i>Chemotherapy</i>. 2017;62(2):100-104. doi:10.1159/000449422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/27788499/pubmed" id="27788499" target="_blank">27788499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27956267">
<a name="27956267"></a>Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. <i>Clin Microbiol Infect</i>. 2017;23(6):363-372. doi:10.1016/j.cmi.2016.12.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/27956267/pubmed" id="27956267" target="_blank">27956267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 1, 2022d. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 1, 2022c. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.2">
<a name="Gupta.2"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 1, 2022a. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.3">
<a name="Gupta.3"></a>Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed October 13, 2022b. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.4">
<a name="Gupta.4"></a>Gupta K. Urinary tract infections and asymptomatic bacteriuria in pregnancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed March 11, 2022c. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.<i> Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-318971">
<a name="318971"></a>Hendlin D, Celozzi E, Weissberger B, Foltz EL. Effect of fosfomycin on the fecal microflora of man. <i>Chemotherapy</i>. 1977;23(suppl 1):117-126. doi:10.1159/000222037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/318971/pubmed" id="318971" target="_blank">318971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31660360">
<a name="31660360"></a>Hocquart M, Pham T, Kuete E, Tomei E, Lagier JC, Raoult D. Successful fecal microbiota transplantation in a patient suffering from irritable bowel syndrome and recurrent urinary tract infections. <i>Open Forum Infect Dis</i>. 2019;6(10):ofz398. doi:10.1093/ofid/ofz398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/31660360/pubmed" id="31660360" target="_blank">31660360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29710295">
<a name="29710295"></a>Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. <i>JAMA</i>. 2018;319(17):1781-1789. doi:10.1001/jama.2018.3627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29710295/pubmed" id="29710295" target="_blank">29710295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26437630">
<a name="26437630"></a>Iarikov D, Wassel R, Farley J, Nambiar S. Adverse events associated with fosfomycin use: Review of the literature and analyses of the FDA adverse event reporting system database. <i>Infect Dis Ther</i>. 2015;4(4):433-458. doi:10.1007/s40121-015-0092-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/26437630/pubmed" id="26437630" target="_blank">26437630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ivozfo.1">
<a name="Ivozfo.1"></a>Ivozfo (fosfomycin) [product monograph]. Mississauga, Ontario, Canada: Verity Pharmaceuticals; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26921414">
<a name="26921414"></a>Jacobson S, Junco Noa L, Ahmed S, Wallace MR. Efficacy and safety of oral fosfomycin for urinary tract infections in hospitalized patients. <i>Antimicrob Agents Chemother</i>. 2016;60(3):1952. doi:10.1128/AAC.02971-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/26921414/pubmed" id="26921414" target="_blank">26921414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30796442">
<a name="30796442"></a>Karaiskos I, Galani L, Sakka V, et al. Oral fosfomycin for the treatment of chronic bacterial prostatitis.<i> J Antimicrob Chemother</i>. 2019;74(5):1430-1437. doi:10.1093/jac/dkz015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/30796442/pubmed" id="30796442" target="_blank">30796442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30861061">
<a name="30861061"></a>Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial. <i>Clin Infect Dis</i>. 2019;69(12):2045-2056. doi:10.1093/cid/ciz181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/30861061/pubmed" id="30861061" target="_blank">30861061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-832510">
<a name="832510"></a>Kirby WM, "Pharmacokinetics of Fosfomycin," <i>Chemotherapy</i>, 1977, 23(Suppl 1):141-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/832510/pubmed" id="832510" target="_blank">832510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34151754">
<a name="34151754"></a>Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women - a systematic review and meta-analysis. <i>J Chemother</i>. 2022;34(3):139-148. doi:10.1080/1120009X.2021.1938949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/34151754/pubmed" id="34151754" target="_blank">34151754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32961833">
<a name="32961833"></a>Leelawattanachai P, Wattanavijitkul T, Paiboonvong T, et al. Evaluation of intravenous fosfomycin disodium dosing regimens in critically ill patients for treatment of carbapenem-resistant enterobacterales infections using Monte Carlo simulation. <i>Antibiotics (Basel)</i>. 2020;9(9):615. doi:10.3390/antibiotics9090615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/32961833/pubmed" id="32961833" target="_blank">32961833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28295441">
<a name="28295441"></a>Loethen AA, Kerstenetzky L, Descourouez JL, Leverson GE, Smith JA, Jorgenson MR. Fosfomycin for the treatment of cystitis in the abdominal solid organ transplant population. <i>Pharmacotherapy</i>. 2017;37(5):599-606. doi:10.1002/phar.1924.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/28295441/pubmed" id="28295441" target="_blank">28295441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666924">
<a name="26666924"></a>Los-Arcos I, Pigrau C, Rodríguez-Pardo D, et al. Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis. <i>Antimicrob Agents Chemother.</i> 2015;60(3):1854-1858. doi:10.1128/AAC.02611-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/26666924/pubmed" id="26666924" target="_blank">26666924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28868940">
<a name="28868940"></a>Mannucci C, Dante G, Miroddi M, et al. Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin. <i>J Matern Fetal Neonatal Med.</i> 2019;32(1):125-128. doi:10.1080/14767058.2017.1373761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/28868940/pubmed" id="28868940" target="_blank">28868940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21945848">
<a name="21945848"></a>Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. <i>Int J Infect Dis</i>. 2011;15(11):e732-e739. doi:10.1016/j.ijid.2011.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/21945848/pubmed" id="21945848" target="_blank">21945848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Monurol.1">
<a name="Monurol.1"></a>Monurol (fosfomycin tromethamine) [prescribing information]. Madison, NJ: Allergan USA, Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Clinical Guideline Centre (NICE). Drug allergy: Diagnosis and management of drug allergy in adults, children and young people. 2014: NICE clinical guideline 183. Updated November 2018. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926565">
<a name="22926565"></a>Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. <i>Antimicrob Agents Chemother</i>. 2012;56(11):5744-5748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/22926565/pubmed" id="22926565" target="_blank">22926565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nicolle.1">
<a name="Nicolle.1"></a>Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2019;68(10):e83-e110.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23880170">
<a name="23880170"></a>Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. <i>Int J Antimicrob Agents</i>. 2013;42(4):289-293. doi:10.1016/j.ijantimicag.2013.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/23880170/pubmed" id="23880170" target="_blank">23880170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26239990">
<a name="26239990"></a>Parker SL, Frantzeskaki F, Wallis SC, et al. Population pharmacokinetics of fosfomycin in critically ill patients. <i>Antimicrob Agents Chemother</i>. 2015;59(10):6471-6476. doi:10.1128/AAC.01321-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/26239990/pubmed" id="26239990" target="_blank">26239990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9098664">
<a name="9098664"></a>Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. <i>Drugs</i>. 1997;53(4):637-656. doi:10.2165/00003495-199753040-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/9098664/pubmed" id="9098664" target="_blank">9098664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31302868">
<a name="31302868"></a>Philipps W, Fietz AK, Meixner K, et al. Pregnancy outcome after first-trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study. <i>Infection</i>. 2020;48(1):57-64. doi:10.1007/s15010-019-01342-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/31302868/pubmed" id="31302868" target="_blank">31302868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2085989">
<a name="2085989"></a>Principi N, Corda R, Bassetti D, Varese LA, Peratoner L. Fosfomycin trometamol versus netilmicin in children's lower urinary tract infections. <i>Chemotherapy</i>. 1990;36(suppl 1):S41-S45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/2085989/pubmed" id="2085989" target="_blank">2085989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37190910">
<a name="37190910"></a>Purcell R, Yeoh D, Bowen A, et al. A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents. <i>J Antimicrob Chemother</i>. 2023;78(7):1616-1621. doi:10.1093/jac/dkad131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/37190910/pubmed" id="37190910" target="_blank">37190910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24309172">
<a name="24309172"></a>Qiao LD, Zheng B, Chen S, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. <i>BMJ Open</i>. 2013;3(12):e004157. doi:10.1136/bmjopen-2013-004157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/24309172/pubmed" id="24309172" target="_blank">24309172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1294525">
<a name="1294525"></a>Reeves DS. Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamol: A review. Infection. 1992;20(Suppl 4):S313-S316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/1294525/pubmed" id="1294525" target="_blank">1294525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9788697">
<a name="9788697"></a>Rosales MJ, Vega F. Anaphylactic shock due to fosfomycin. <i>Allergy</i>. 1998;53(9):905-907. doi:10.1111/j.1398-9995.1998.tb04002.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/9788697/pubmed" id="9788697" target="_blank">9788697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16080282">
<a name="16080282"></a>Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. <i>Arzneimittelforschung</i>. 2005;55(7):420-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/16080282/pubmed" id="16080282" target="_blank">16080282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20800792">
<a name="20800792"></a>Sánchez-Morillas L, Pérez-Ezquerra PR, Reaño-Martos M, Mayorga C, Laguna-Martínez JJ. Anaphylaxis induced by fosfomycin. <i>Ann Allergy Asthma Immunol</i>. 2010;105(3):241. doi:10.1016/j.anai.2010.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/20800792/pubmed" id="20800792" target="_blank">20800792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26923259">
<a name="26923259"></a>Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. <i>J Infect Chemother</i>. 2016;22(5):273-280. doi:10.1016/j.jiac.2016.01.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/26923259/pubmed" id="26923259" target="_blank">26923259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35422698">
<a name="35422698"></a>Scavone C, Mascolo A, Bernardi FF, et al. Hypernatremia during intravenous treatment with fosfomycin: A retrospective medical record review study and an analysis of spontaneous reports in the EudraVigilance database.<i> Front Pharmacol</i>. 2022;13:844122. doi:10.3389/fphar.2022.844122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/35422698/pubmed" id="35422698" target="_blank">35422698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27272722">
<a name="27272722"></a>Schmidt JJ, Bode-Böger SM, Wilhelmi M, et al. Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing. <i>J Antimicrob Chemothe</i>r. 2016;71(9):2673-2674. doi:10.1093/jac/dkw187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/27272722/pubmed" id="27272722" target="_blank">27272722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34995367">
<a name="34995367"></a>Schulz GS, Schütz F, Spielmann FVJ, da Ros LU, de Almeida JS, Ramos JGL. Single-dose antibiotic therapy for urinary infections during pregnancy: a systematic review and meta-analysis of randomized clinical trials. <i>Int J Gynaecol Obstet</i>. 2022;159(1):56-64. doi:10.1002/ijgo.14087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/34995367/pubmed" id="34995367" target="_blank">34995367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28901793">
<a name="28901793"></a>Shorr AF, Pogue JM, Mohr JF. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections. <i>Expert Rev Anti Infect Ther</i>. 2017;15(10):935-945. doi:10.1080/14787210.2017.1379897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/28901793/pubmed" id="28901793" target="_blank">28901793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35024838">
<a name="35024838"></a>Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, et al; REIPI-GEIRAS-FOREST group. Effectiveness of fosfomycin for the treatment of multidrug-resistant <i>Escherichia coli</i> bacteremic urinary tract infections: A randomized clinical trial. <i>JAMA Netw Open</i>. 2022;5(1):e2137277. doi:10.1001/jamanetworkopen.2021.37277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/35024838/pubmed" id="35024838" target="_blank">35024838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29660401">
<a name="29660401"></a>Spoletini G, Kennedy M, Flint L, et al. Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre. <i>Pulm Pharmacol Ther</i>. 2018;50:82-87. doi:10.1016/j.pupt.2018.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29660401/pubmed" id="29660401" target="_blank">29660401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999027">
<a name="27999027"></a>Staley C, Vaughn BP, Graiziger CT, Sadowsky MJ, Khoruts A. Gut-sparing treatment of urinary tract infection in patients at high risk of <i>Clostridium difficile</i> infection. <i>J Antimicrob Chemother</i>. 2017;72(2):522-528. doi:10.1093/jac/dkw499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/27999027/pubmed" id="27999027" target="_blank">27999027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10890258">
<a name="10890258"></a>Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. <i>Clin Ther</i>. 1999;21(11):1864-1872. doi:10.1016/S0149-2918(00)86734-X.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/10890258/pubmed" id="10890258" target="_blank">10890258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21653301">
<a name="21653301"></a>Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of <i>Clostridium difficile</i> infection. <i>Clin Infect Dis</i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/21653301/pubmed" id="21653301" target="_blank">21653301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34791074">
<a name="34791074"></a>Ten Doesschate T, Kuiper S, van Nieuwkoop C, et al; FORECAST Study Team. Fosfomycin vs ciprofloxacin as oral step-down treatment for <i>Escherichia coli</i> febrile urinary tract infections in women: A randomized, placebo-controlled, double-blind, multicenter trial. <i>Clin Infect Dis</i>. 2022;75(2):221-229. doi:10.1093/cid/ciab934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/34791074/pubmed" id="34791074" target="_blank">34791074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22564843">
<a name="22564843"></a>Tobudic S, Matzneller P, Stoiser B, et al. Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. <i>Antimicrob Agents Chemother</i>. 2012;56(7):3992-3995. doi:10.1128/AAC.00126-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/22564843/pubmed" id="22564843" target="_blank">22564843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34030567">
<a name="34030567"></a>Tsegka KG, Voulgaris GL, Kyriakidou M, Kapaskelis A, Falagas ME. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. <i>Expert Rev Anti Infect Ther</i>. 2022;20(1):33-43. doi:10.1080/14787210.2021.1932463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/34030567/pubmed" id="34030567" target="_blank">34030567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8298585">
<a name="8298585"></a>Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. <i>Pharm World Sci</i>. 1993;15(6):257-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/8298585/pubmed" id="8298585" target="_blank">8298585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis.<i> Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3552696">
<a name="3552696"></a>Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children's lower urinary tract infections. <i>Eur Urol</i>. 1987;13(suppl 1):S119-S121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/3552696/pubmed" id="3552696" target="_blank">3552696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32417205">
<a name="32417205"></a>Wang T, Wu G, Wang J, et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: a systematic review and meta-analysis. <i>Int J Antimicrob Agents.</i> 2020;56(1):106018. doi:10.1016/j.ijantimicag.2020.106018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/32417205/pubmed" id="32417205" target="_blank">32417205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891606">
<a name="29891606"></a>Wenzler E, Bleasdale SC, Sikka M, et al; Antibacterial Resistance Leadership Group. Phase I study To evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. <i>Antimicrob Agents Chemother</i>. 2018;62(8):e00464-18. doi:10.1128/AAC.00464-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosfomycin-drug-information/abstract-text/29891606/pubmed" id="29891606" target="_blank">29891606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8477 Version 256.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
